CSL (CSJ) AI Stock Analysis

CSL

(BX Swiss:CSJ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationPositive operating cash flow despite the reported loss demonstrates that CSL’s core businesses continue to convert activity into funding. This supports dividends, buybacks, investment in capacity and product development, while providing resilience through portfolio remediation.

Negative Factors

Large impairments and statutory lossThe scale of impairments and the statutory loss indicate that previously recorded asset values and earnings expectations have been materially reset. This weakens recent earnings quality, reduces equity support and raises the burden on management to restore returns.

CSL (CSJ) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 64.78B
Dividend Yield: 2.03%
Average Volume (3M): 196
Price to Earnings (P/E): -26.7
Beta (1Y): 1.19
Revenue Growth: -6.92%
EPS Growth: -178.57%
Country: Switzerland
Employees: 29,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CSL Business Overview & Revenue Model

Company Description

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets suc...

CSL Earnings Call Summary

Earnings Call Date:Aug 16, 2026(Q4-2026)|% Change Since:56.85%|Next Earnings Date:Feb 08, 2027

Earnings Call SentimentNegative

The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.

Positive Updates

Solid cash generation and shareholder returns

Operating cash flow of $3.5B supported completion of an AUD 1.0B buyback in FY'26, maintenance of the full-year dividend at $2.92 per share (U.S. dollars), and an authorized further buyback of ~AUD 1.1B for FY'27.

Negative Updates

Substantial impairments and statutory loss

FY'26 pretax impairments totaled $7.1B (including $5.5B in H2); the largest component was Vifor impairments of $4.1B. After restructuring and impairments, statutory NPAT attributable to shareholders was a loss of $2.6B.

Company Guidance

CSL guided FY‑27 group revenue to be broadly in line with FY‑26 (FY‑26 revenue $15.8bn, down 1% constant FX) and underlying NPAT to grow roughly 5% at constant currency (excluding restructuring and impairments), while warning of an approximately $50m FX headwind at current rates; division guidance was Behring mid‑single‑digit revenue growth with Ig mid‑ to high‑single‑digit growth and a modest gross‑margin improvement (aiming to recover roughly the ~70bp lost in FY‑26), Seqirus low‑single‑digit growth, and Vifor an ~25% revenue decline (no TAVNEOS sales in FY‑27, Velphoro TDAPA benefit ceasing end‑2026). Management expects FY‑27 incremental transformation savings of ~ $220m (taking annualized savings to ~ $400m and up to $550m in FY‑28) with about half to be reinvested into commercial and R&D, FY‑27 CapEx of ~ $1.0bn ± $100m, a new AUD 1.1bn buyback (after the AUD 1bn completed in FY‑26), maintained FY‑26 dividend (final $1.62, full year $2.92 per share), strong operating cash flow ($3.5bn in FY‑26), and a target net debt/EBITDA range of 1.5–2x (FY‑26 net debt/EBITDA 1.8x).

CSL Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:CSJ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	64Neutral	AUD 2.94B	-35.83	-10.06%	―	555.67%	49.08%
AU:TLX	53Neutral	AUD 4.47B	96.62	7.24%	―	26.66%	179.32%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CU6	40Underperform	AUD 585.74M	-5.41	-51.15%	―	―	-44.83%
AU:SPL	40Underperform	AUD 217.31M	-26.32	-42.35%	―	145.32%	25.75%

* Healthcare Sector Average

Performance Comparison

CH:CSJ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:CSJ	CSL Limited	113.77	47.06	70.54%
AU:MSB	Mesoblast Limited	2.26	-0.22	-8.87%
AU:SPL	Starpharma Holdings Limited	0.45	0.11	32.35%
AU:TLX	Telix Pharmaceuticals Ltd.	13.13	-2.68	-16.95%
AU:CU6	Clarity Pharmaceuticals Ltd.	1.57	-3.25	-67.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CSL AI Stock Analysis